Why Is AMLX Stock Popping 14% After Hours?
Amylyx Pharmaceuticals (AMLX) shares rose 14% after-hours as it prepares to release Phase 3 trial results for avexitide, its lead drug candidate for post-bariatric hypoglycemia. The trial's success could support a 2027 regulatory filing. AMLX has no FDA-approved therapies currently, and its cash runway extends into 2028. Mizuho raised its price target to $30, citing potential launch pricing updates.
How this was made
The 30-second read
Why it matters
The trial readout could validate the drug's efficacy, unlocking a potential 2027 launch and boosting valuation.
Market read
A 14% after‑hours surge highlights immediate market interest; the upcoming data release is a high‑impact catalyst.
What to watch
Cash runway to 2028 reduces financing risk; prior ALS failure may temper enthusiasm.
Background
Amylyx's lead program avexitide targets post‑bariatric hypoglycemia, a niche indication with FDA Breakthrough Therapy status.
Ticker impact
Shares jumped 14% after-hours as Amylyx announced it will release Phase 3 LUCIDITY trial results for avexitide tomorrow.
Potential 20%+ move on positive data; downside risk if results disappoint.
Biotech stocks typically experience large moves around pivotal trial announcements; the stock already reacted strongly to the news.
Market effects
May lift sentiment in the rare‑disease biotech sector.
Limited to US biotech investors.
Minimal beyond niche biotech community.
Counterpoint
If the trial fails, the stock could sharply reverse the recent rally.
Key entities
- companyAmylyx Pharmaceuticals Inc.
Biotech developer of avexitide.
